Drugs / SYS6010
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07692048 | Jun 2026 → Dec 2027 expected | non-small cell lung carcinoma | Sichuan University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05948865 | Jun 2023 → May 2027 expected | lung carcinoma | Conjupro Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07472647 | Feb 2026 → Feb 2029 expected | non-small cell lung carcinoma, small cell lung carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07241936 | Nov 2025 → Oct 2027 expected | cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06775236 | Mar 2025 → Jun 2027 expected | breast cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07254585 | Dec 2025 → Jun 2026 overdue | head and neck squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07256509 | Nov 2025 → Nov 2026 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07251062 | Dec 2025 → Dec 2029 expected | esophageal squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07672223 | Jun 2026 → Sep 2029 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07633873 | Jun 2026 → Sep 2027 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07376382 | Jun → Dec 2026 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07406542 | Apr 2026 → Apr 2029 expected | Her2-receptor negative breast cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07417735 | Mar 2026 → Dec 2028 expected | esophageal squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07442565 | Mar 2026 → Dec 2027 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06927986 | Mar 2025 → Jul 2026 overdue | — | CSPC Megalith Biopharmaceutical Co.,Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07104877 | Apr → Nov 2024 overdue | colorectal cancer, gastric cancer | Fujian Cancer Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07633873 ↗ |
| Known as | CPO301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05948865 ↗ |
| Action | Inhibit | “anti-EGFR” NCT07251062 ↗ |
| Modality | Monoclonal antibody | “anti-EGFR monoclonal antibody” NCT06775236 ↗ |
| Route | Intravenous | “Administered by intravenous injection” NCT05948865 ↗ |
| Target | EGFR | “EGFR-targeting antibody-drug conjugate” NCT05948865 ↗ |